A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

UltraSight Collaboration with GE Healthcare will bring Wireless Cardiac Point of Care Ultrasound to Space

Technology developed through partnership to monitor astronaut's heart during 'Rakia' space mission

UltraSight, a digital health pioneer transforming cardiac imaging through the power of AI, announced a new collaboration with GE Healthcare to conduct a cardiac study aboard the Axiom ‘Rakia’ space mission, and the successful completion of Preliminary Design Review (PDR) for Cardiac Point of Care Ultrasound (POCUS).

During the study, UltraSight’s real-time AI guidance software and GE Healthcare’s handheld GE Vscan Air, the high performance, wireless pocket-sized color ultrasound, will record images of an astronaut’s heart in microgravity.

The goal of this study is to demonstrate how, using the right technology, accurate, cardiac ultrasound images can be acquired anywhere – even in space – and how AI guidance has the potential to enable successful scanning with limited training. During the mission, Lt. Col. Eytan Stibbe, the first Israeli flying to the International space station, will use the Vscan Air ultrasound device with UltraSight AI guidance and take his own cardiac images, independent of trained medical professionals or ground mission control. The outcomes of this study could potentially benefit millions of cardiology patients worldwide, particularly in underserved communities where access to echocardiography labs and large medical systems is limited.

“Easy access to cardiac diagnostic imaging and a small and durable, wireless ultrasound device that can perform under arduous space conditions would be hugely important – it could allow the monitoring of space crews’ health and provide critical information on whether immediate intervention is necessary,” said Davidi Vortman, CEO of UltraSight. “Vscan Air fits the bill. We are excited to collaborate with GE Healthcare and lead a new wave of medical innovation in space.”

“Space agencies are looking for an ultrasound solution with the features provided by GE Healthcare and UltraSight not only for the international space station, but to also assist with upcoming missions including Artemis to the moon, and soon after to Mars,” said Eran Schenker, MD, Chief Innovation Medical Officer, Israeli Aerospace Medicine Institute (IAMI). “In fact, the mission to Mars, which will have significant communication challenges and delays, will require the rethinking of telemedicine. Real-time AI guidance will be critical in enabling the crew to obtain cardiac images without relying on mission control on Earth,” he concluded.

GE Healthcare pioneered the first color pocket-sized ultrasound, Vscan, in 2010 and has since continued to revolutionize the way clinicians use handheld ultrasound to see patients. To date, there are over 30,000 Vscan Family systems in the pockets of clinicians, impacting the care of more than 50 million patients worldwide. The Vscan Air, launched earlier this year, increases access to precise care, helping improve workflow efficiencies and patient outcomes through dual-probe whole-body scanning capabilities and a user-friendly interface.

“The upcoming space mission aims to demonstrate the added value AI could have for Point of Care Ultrasound in providing flexible and timely access to diagnostic information anywhere and anytime,” said James Hurley, General Manager, Handheld Ultrasound at GE Healthcare.  “From the farthest place you can imagine, which is space, to the primary and acute care settings in local communities worldwide, this technology plays a critical role in providing patients with accurate and timely diagnosis of cardiac conditions and other diseases.

The ‘Rakia’ Preliminary Design Review was completed after the technology was presented to the Scientific Program Committee, Israeli Space Authority, Ramon Foundation and to Col. Stibbe. Its successful completion is a key milestone in the process of any project intended for space missions, as it identifies potential issues and ensures the design will help meet all space mission requirements.

After meeting UltraSight’s medical team and being introduced to the technology, Col. Stibbe said, “I am happy to play a role in testing medical innovation that has the potential to improve patient access to advanced medical care around the world. Even in 2021, too many people still do not have access to advanced healthcare. This is a step in the right direction.”

In May 2021, UltraSight was selected by the Israel Space Agency to conduct the cardiac study aboard the ‘Rakia’ space mission. The company chose GE Healthcare as a partner because of its R&D expertise and the high image quality of the Vscan Air.

UltraSight is a partner in GE Healthcare’s Edison™ Developer Program, a dynamic ecosystem which helps innovators deliver advanced healthcare applications, integrate products, and drive commercial growth.

This is not the first time a GE Healthcare ultrasound device was used in space. In July 2011, GE Healthcare’s Vividq cardiovascular ultrasound system was delivered to the International Space Station (ISS) on the Atlantis’ final space shuttle flight.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy